BACKGROUND: @entity8 ( @entity8 ) represents a potential treatment option for certain @entity1 with resistant arterial @entity101 ( @entity101 ). @entity101 is associated with @entity32 and remodeling, contributing to progressive @entity1504 , and @entity731 . The present study aimed to evaluate the influence of @entity8 on @entity65 and remodeling by determining serum levels of @entity650 ( @entity650 ), high-sensitive @entity1851 (hsCRP), matrix metalloproteinases (MMP), and @entity2843 ( @entity2843 ). METHODS: A total of 60 consecutive @entity1 (age 67.9      9.6  years) undergoing @entity8 were included. A therapeutic response was defined as an office systolic blood pressure (SBP) reduction of >10  mmHg 6  months after @entity8 . Venous serum samples for measurement of hsCRP, @entity650 , @entity1476 , @entity1495 , and @entity2843 were collected prior to and 6  months after @entity8 . RESULTS: A significant reduction in office SBP of 26.4  mmHg [SBPbaseline 169.3  mmHg (SD 11.3), p  <  0.001] was documented 6  months after @entity8 . The serum levels of hsCRP (p  <  0.001) and the pro-inflammatory cytokine @entity650 (p  <  0.001) were significantly decreased compared to baseline values. The levels of @entity1495 (p  =  0.024) and @entity1476 (p  <  0.01) were significantly increased compared to baseline values. CONCLUSION: In addition to the effective blood pressure reduction in response to @entity8 , this study demonstrates a positive effect of @entity8 on biomarkers reflecting @entity32 and remodeling. These results suggest a possible prognostic benefit of @entity8 in high-risk @entity1 for @entity409 and @entity65 as well as end-organ damage.

Beneficial effects of renal sympathetic denervation on @entity65 and remodeling in essential XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['chronic vascular inflammation', 'vascular inflammation'] @entity8 :: ('MESH:D007674', 'Disease') :: ['Renal sympathetic denervation', 'RSD'] @entity650 :: ('3569', 'Gene') :: ['IL-6', 'interleukin-6'] @entity101 :: ('MESH:D006973', 'Disease') :: ['HT', 'hypertension'] @entity1476 :: ('4313', 'Gene') :: ['MMP-2'] @entity409 :: ('MESH:D008107', 'Disease') :: ['endothelial dysfunction'] @entity1504 :: ('MESH:D002561', 'Disease') :: ['vascular damage'] @entity2843 :: ('7076', 'Gene') :: ['tissue inhibitor of metalloproteinases', 'TIMP', 'TIMP-1'] @entity1495 :: ('4318', 'Gene') :: ['MMP-9'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular inflammation', 'cardiovascular remodeling'] @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein']
@entity101 :: (MESH:D006973,Disease) :: ['hypertension']
